GSK and Novartis withdraw EU filings in cancer and influenza
This article was originally published in Scrip
GlaxoSmithKline and Novartis have each withdrawn a marketing authorisation application for Tyverb and Fluad respectively, the EMA has announced ahead of the outcome of this month's meeting of its advisory group, the Committee for Medicinal Products for Human Use (CHMP).
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.